Straits Times Index
3,272.72 +47.55 (+1.47%) S&P 500
5,062.66 +52.06 (+1.04%) Dow
38,433.62 +193.64 (+0.51%) Nasdaq
15,675.95 +224.64 (+1.45%) Bitcoin USD
67,107.94 +751.61 (+1.13%) CMC Crypto 200
1,438.07 +23.31 (+1.65%)
ProKidney Corp. (PROK)
| Previous close | 2.7200 |
| Open | 2.7200 |
| Bid | 2.0100 x 200 |
| Ask | 3.3500 x 200 |
| Day's range | 2.6000 - 2.8500 |
| 52-week range | 1.1200 - 13.5100 |
| Volume | |
| Avg. volume | 698,516 |
| Market cap | 1.785B |
| Beta (5Y monthly) | 1.29 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.5700 |
| Earnings date | 03 May 2024 - 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.00 |
GlobeNewswireProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations
Dr. Ulrich Ernst joins as Executive Vice President of Technical Operations with a deep background and expertise in process development and manufacturing of cell therapies Mr. Lucio Tozzi joined in January of 2024 as Senior Vice President of Global Clinical Operations having over 30 years of experience in clinical trial execution WINSTON-SALEM, N.C., March 25, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutic
- GlobeNewswire
ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights
WINSTON-SALEM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the year ended December 31, 2023. “We are very excited about the future of ProKidney. Building on the positive interim Phase 2 data that we released last Fall for rilparencel (which we sometimes refer to as REACT®) demonstrating the potential
- GlobeNewswire
ProKidney to Participate in Jefferies Biotech on the Bay Summit
WINSTON-SALEM, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the Jefferies Biotech on the Bay Summit being held in Miami on March 12 – 13, 2024. The ProKidney management team will host one-on-one meetings during the event. Interested investors should contact their Jefferies
